Herein, we combined a derivative of cisplatin (CP) and the chemosensitizer lonidamine (LND) to design an amphiphilic prodrug, in which the ratio of LND to cisplatin was fixed at 2:1. Diaminedichlorodihydroxyplatinum (DH-CP) is a hydrophilic cisplatin derivative. Due to its appropriate amphiphilicity, this prodrug could self-assemble into stable nanoparticles (denoted as LNP-NPs). Under the action of excessive glutathione (GSH) in tumor cells, DH-CP could be reduced to cytotoxic cisplatin. In addition, the released LND could inhibit the metabolic process of tumor cells, and improving the sensitivity of tumor cells to cisplatin. In vitro studies demonstrated that LNP-NPs displayed significantly cytotoxicity on breast cancer cells, and the cell viability after co-incubation for 48 h (CP 16 μg/mL) were 18.77% (MCF-7) and 20.01% (EMT6), respectively. LNP-NPs could also significantly inhibit the growth of MCF-7 tumor-like spheroids, which were realized through the high coordination and cooperation between CP and LND. Therefore, the carrier-free drug delivery system based on LND and DH-CP is expected to achieve a good synergistic anti-tumor effect.
ChenHBGuZJAnHW, et al.Precise nanomedicine for intelligent therapy of cancer. Sci China Chem2018; 61: 1503–1552.
2.
WuLLengDLCunDM, et al.Advances in combination therapy of lung cancer: Rationales, delivery technologies and dosage regimens. J Control Release2017; 260: 78–91.
3.
KoziolováEJanouškováOCuchalováL, et al.Overcoming multidrug resistance in Dox-resistant neuroblastoma cell lines via treatment with HPMA copolymer conjugates containing anthracyclines and P-gp inhibitors. J Control Release2016; 233: 136–146.
4.
RajendranLKnölkerHJSimonsK. Subcellular targeting strategies for drug design and delivery. Nat Rev Drug Discov2010; 9: 29–42.
FuXShiYQiT, et al.Precise design strategies of nanomedicine for improving cancer therapeutic efficacy using subcellular targeting. Signal Transduct Tar2020; 5: 1–15.
7.
FuldaSGalluzziLKroemerG. Targeting mitochondria for cancer therapy. Nat Rev Drug Discov2010; 9: 447–464.
8.
YuPYuHGuoC, et al.Reversal of doxorubicin resistance in breast cancer by mitochondria-targeted pH-responsive micelles. ACTA Biomater2015; 14: 115–124.
9.
MaoGKrausG AKimI, et al.Effect of a mitochondria-targeted vitamin E derivative on mitochondrial alteration and systemic oxidative stress in mice. Br J Nutr2011; 106: 87–95.
10.
WangXXLiYBYaoHJ, et al.The use of mitochondrial targeting resveratrol liposomes modified with a dequalinium polyethylene glycol-distearoylphosphatidyl ethanolamine conjugate to induce apoptosis in resistant lung cancer cells. Biomaterials2011; 32: 5673–5687.
11.
DongLFJamesonVJATillyD, et al.Mitochondrial targeting of vitamin E succinate enhances its pro-apoptotic and anti-cancer activity via mitochondrial complex II. J Biol Inorg Chem2011; 286: 3717–3728.
12.
ChengGZielonkaJMcAllisterDM, et al.Mitochondria-targeted vitamin E analogs inhibit breast cancer cell energy metabolism and promote cell death. BMC Cancer2013; 13: 1–14.
13.
ZhangZLiuZMaL, et al.Reversal of multidrug resistance by mitochondrial targeted self-assembled nanocarrier based on stearylamine. Mol Pharmaceut2013; 10: 2426–2434.
14.
ChengGZielonkaJDrankaBP, et al.Mitochondria-targeted drugs synergize with 2-deoxyglucose to trigger breast cancer cell death. Cancer Res2012; 72: 2634–2644.
15.
Cohen-ErezIIssacsonCLaviY, et al.Antitumor effect of lonidamine-polypeptide-peptide nanoparticles in breast cancer models. ACS Appl Mater Inter2019; 11: 32670–32678.
16.
WangFOgasawaraMAHuangP. Small mitochondria-targeting molecules as anti-cancer agents. Mol Aspects Med2010; 31: 75–92.
17.
BrawerMK. Lonidamine: basic science and rationale for treatment of prostatic proliferative disorders. Rev Urol2005; 7: S21–S26.
18.
HuangYSunGSunX, et al.The potential of lonidamine in combination with chemotherapy and physical therapy in cancer treatment. Cancers2020; 12: 3332.
19.
NathKGuoLNancolasB, et al.Mechanism of antineoplastic activity of lonidamine. BBA-Rev Cancer1866; 20161866: 151–162.
20.
AssanhouAGLiWZhangL, et al.Reversal of multidrug resistance by co-delivery of paclitaxel and lonidamine using a TPGS and hyaluronic acid dual-functionalized liposome for cancer treatment. Biomaterials2015; 73: 284–295.
21.
FanciulliMBrunoTGiovannelliA, et al.Energy metabolism of human LoVo colon carcinoma cells: correlation to drug resistance and influence of lonidamine. Clin Cancer Res2000; 6: 1590–1597.
22.
PengYLuJLiR, et al.Glucose and Triphenylphosphonium Co-Modified Redox-Sensitive Liposomes to Synergistically Treat Glioma with Doxorubicin and Lonidamine. ACS Appl Mater Inter2021; 13: 26682–26693.
23.
LiYCFungKPKwokTT, et al.Mitochondrial targeting drug lonidamine triggered apoptosis in doxorubicin-resistant HepG2 cells. Life Sci71 : 2002; 71: 2729–2740.
24.
JinXZhouJZhangZ, et al.Doxorubicin combined with betulinic acid or lonidamine in RGD ligand-targeted pH-sensitive micellar system for ovarian cancer treatment. Int J Pharmaceut2019; 571: 118751.
25.
LiuYZhangXZhouM, et al.Mitochondrial-targeting lonidamine-doxorubicin nanoparticles for synergistic chemotherapy to conquer drug resistance. ACS Appl Mater Inter2017; 9: 43498–43507.
26.
Di CosimoSFerrettiGPapaldoP, et al.Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors. Drug Today2003; 39: 157–174.
27.
QuWYangQWangG, et al.Amphiphilic irinotecan–melampomagnolide B conjugate nanoparticles for cancer chemotherapy. RSC Adv2020; 10: 8958–8966.
28.
GaoCBhattaraiPChenM, et al.Amphiphilic drug conjugates as nanomedicines for combined cancer therapy. Bioconjug Chem29 : 2018; 29: 3967–3981.
29.
WangZChenJLittleN, et al.Self-assembling prodrug nanotherapeutics for synergistic tumor targeted drug delivery. Acta Biomater2020; 111: 20–28.
30.
QinSYZhangAQChengSX, et al.Drug self-delivery systems for cancer therapy. Biomaterials2017; 112: 234–247.
31.
ChenHChenFHuW, et al.Effective platinum (IV) prodrugs conjugated with lonidamine as a functional group working on the mitochondria. J Inorg Biochem2018; 180: 119–128.
32.
AngioliRJanicekMSevinBU, et al.Use of lonidamine to potentiate the effect of cisplatin and carboplatin on platinum resistant human ovarian cancer cells. Int J Surg Oncol1997; 11: 777–780.
33.
De CesareMPratesiGGiustiA, et al.Stimulation of the apoptotic response as a basis for the therapeutic synergism of lonidamine and cisplatin in combination in human tumour xenografts. Br J Cancer1998; 77: 434–439.
34.
ShenWLuanJCaoL, et al.Thermogelling polymer–platinum (IV) conjugates for long-term delivery of cisplatin. Biomacromolecules2015; 16: 105–115.
35.
GuoDXuSHuangY, et al.Platinum (IV) complex-based two-in-one polyprodrug for a combinatorial chemo-photodynamic therapy. Biomaterials2018; 177: 67–77.
36.
ZhangRXingRJiaoT, et al.Carrier-free, chemophotodynamic dual nanodrugs via self-assembly for synergistic antitumor therapy[J]. ACS Appl Mater Inter2016; 8: 13262–13269.
37.
D'IncalciMColomboTUbezioP, et al.The combination of yondelis and cisplatin is synergistic against human tumor xenografts[J]. Eur J Cancer2003; 39: 1920–1926.
38.
YooJ WChambersEMitragotriS. Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects. Cure Pharm Des2010; 16: 2298–2307.
39.
LeeCCMacKayJAFréchetJMJ, et al.Designing dendrimers for biological applications. Nat Biotechnol2005; 23: 1517–1526.
40.
NaeyeBDeschoutHCaveliersV, et al.In vivo disassembly of IV administered siRNA matrix nanoparticles at the renal filtration barrier. Biomaterials2013; 34: 2350–2358.
41.
Soo ChoiHLiuWMisraP, et al.Renal clearance of quantum dots. Nat Biotechnol2007; 25: 1165–1170.
42.
WangJMaoWLockLL, et al.The role of micelle size in tumor accumulation, penetration, and treatment. ACS Nano2015; 9: 7195–7206.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
